Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 39 | 2023 | 169 | 7.140 |
Why?
|
| Hydroxyurea | 7 | 2015 | 34 | 1.390 |
Why?
|
| Antisickling Agents | 6 | 2015 | 15 | 1.350 |
Why?
|
| Hypertension, Pulmonary | 11 | 2017 | 77 | 1.310 |
Why?
|
| Pain | 6 | 2023 | 249 | 1.100 |
Why?
|
| Fetal Hemoglobin | 5 | 2017 | 13 | 1.010 |
Why?
|
| Vascular Diseases | 3 | 2014 | 30 | 0.940 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2014 | 528 | 0.640 |
Why?
|
| Pain Threshold | 1 | 2017 | 24 | 0.630 |
Why?
|
| Haplotypes | 4 | 2014 | 152 | 0.620 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 628 | 0.570 |
Why?
|
| Adult | 30 | 2023 | 11034 | 0.560 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2014 | 638 | 0.530 |
Why?
|
| Humans | 50 | 2023 | 34853 | 0.530 |
Why?
|
| Hemolysis | 6 | 2014 | 39 | 0.520 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 160 | 0.510 |
Why?
|
| Mutation | 5 | 2013 | 1023 | 0.500 |
Why?
|
| GTP Cyclohydrolase | 1 | 2014 | 4 | 0.490 |
Why?
|
| Lipoproteins | 2 | 2013 | 61 | 0.460 |
Why?
|
| Male | 28 | 2021 | 18870 | 0.450 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 28 | 0.450 |
Why?
|
| Female | 29 | 2021 | 19873 | 0.440 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 29 | 0.410 |
Why?
|
| Rhabdomyosarcoma | 1 | 2009 | 1 | 0.370 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2009 | 2 | 0.370 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 14 | 0.370 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 165 | 0.360 |
Why?
|
| Middle Aged | 17 | 2021 | 9642 | 0.350 |
Why?
|
| Hemoglobins | 2 | 2011 | 101 | 0.340 |
Why?
|
| Depression | 1 | 2014 | 664 | 0.320 |
Why?
|
| Genetic Markers | 3 | 2014 | 118 | 0.320 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 423 | 0.310 |
Why?
|
| Young Adult | 10 | 2021 | 4012 | 0.290 |
Why?
|
| Anemia, Aplastic | 2 | 2016 | 2 | 0.280 |
Why?
|
| Adolescent | 13 | 2021 | 5035 | 0.280 |
Why?
|
| Tricuspid Valve Insufficiency | 4 | 2020 | 13 | 0.270 |
Why?
|
| Genetic Variation | 3 | 2014 | 328 | 0.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 150 | 0.260 |
Why?
|
| Iron | 3 | 2014 | 204 | 0.250 |
Why?
|
| Cohort Studies | 6 | 2014 | 1422 | 0.240 |
Why?
|
| Mannose-Binding Lectin | 2 | 2005 | 5 | 0.240 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2023 | 9 | 0.230 |
Why?
|
| Prospective Studies | 6 | 2020 | 1353 | 0.230 |
Why?
|
| alpha-Thalassemia | 3 | 2014 | 4 | 0.230 |
Why?
|
| Prevalence | 3 | 2018 | 1425 | 0.230 |
Why?
|
| Hemoglobinopathies | 1 | 2023 | 5 | 0.230 |
Why?
|
| Volatile Organic Compounds | 1 | 2023 | 15 | 0.230 |
Why?
|
| Aged | 9 | 2021 | 6448 | 0.220 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 18 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 106 | 0.210 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 15 | 0.210 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 968 | 0.190 |
Why?
|
| Ferritins | 3 | 2020 | 54 | 0.190 |
Why?
|
| Orosomucoid | 1 | 2020 | 12 | 0.190 |
Why?
|
| Alleles | 2 | 2014 | 284 | 0.190 |
Why?
|
| Leg Ulcer | 2 | 2011 | 7 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 600 | 0.180 |
Why?
|
| Risk Factors | 7 | 2014 | 3414 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 229 | 0.180 |
Why?
|
| United States | 7 | 2020 | 3894 | 0.180 |
Why?
|
| Thalassemia | 2 | 2009 | 3 | 0.180 |
Why?
|
| Hospitals, Special | 1 | 2018 | 3 | 0.170 |
Why?
|
| Congo | 1 | 2018 | 3 | 0.170 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1056 | 0.170 |
Why?
|
| Patient Care | 1 | 2018 | 28 | 0.170 |
Why?
|
| Phenotype | 2 | 2014 | 650 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2017 | 1349 | 0.170 |
Why?
|
| Child | 8 | 2023 | 2875 | 0.170 |
Why?
|
| Survival Rate | 4 | 2020 | 310 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2013 | 371 | 0.160 |
Why?
|
| Bacteria | 1 | 2021 | 245 | 0.160 |
Why?
|
| Touch | 1 | 2017 | 15 | 0.160 |
Why?
|
| Hyperalgesia | 1 | 2017 | 15 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 484 | 0.160 |
Why?
|
| Cold Temperature | 1 | 2017 | 39 | 0.160 |
Why?
|
| Echocardiography | 3 | 2017 | 144 | 0.160 |
Why?
|
| Hematopoiesis | 2 | 2014 | 30 | 0.150 |
Why?
|
| Erythroid Cells | 2 | 2014 | 6 | 0.150 |
Why?
|
| Epoprostenol | 1 | 2017 | 21 | 0.150 |
Why?
|
| Hot Temperature | 1 | 2017 | 120 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2016 | 251 | 0.150 |
Why?
|
| Gene Frequency | 2 | 2014 | 155 | 0.150 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cholesterol, HDL | 2 | 2013 | 87 | 0.140 |
Why?
|
| HIV-1 | 1 | 2021 | 678 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 9 | 0.140 |
Why?
|
| Hematocrit | 2 | 2013 | 18 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2016 | 38 | 0.140 |
Why?
|
| Pregnancy Proteins | 1 | 2014 | 6 | 0.130 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 20 | 0.130 |
Why?
|
| Biological Clocks | 1 | 2014 | 51 | 0.120 |
Why?
|
| Plethysmography | 1 | 2014 | 7 | 0.120 |
Why?
|
| Endothelium | 1 | 2014 | 31 | 0.120 |
Why?
|
| Heme | 1 | 2014 | 69 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 284 | 0.120 |
Why?
|
| Leukemia | 2 | 2005 | 54 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 964 | 0.120 |
Why?
|
| Logistic Models | 2 | 2013 | 894 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 102 | 0.120 |
Why?
|
| Candidiasis | 2 | 2005 | 85 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 243 | 0.120 |
Why?
|
| Base Sequence | 2 | 2013 | 932 | 0.110 |
Why?
|
| Sleep | 1 | 2014 | 122 | 0.110 |
Why?
|
| Suicide | 1 | 2014 | 114 | 0.110 |
Why?
|
| Cation Transport Proteins | 1 | 2012 | 30 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2012 | 48 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2014 | 517 | 0.110 |
Why?
|
| Hospitalization | 1 | 2015 | 370 | 0.110 |
Why?
|
| Genome, Human | 1 | 2013 | 112 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2014 | 562 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2011 | 59 | 0.110 |
Why?
|
| Comorbidity | 1 | 2014 | 606 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2011 | 16 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 455 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 43 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2011 | 82 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 608 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2008 | 77 | 0.100 |
Why?
|
| Cell Lineage | 1 | 2011 | 88 | 0.100 |
Why?
|
| Sex Factors | 1 | 2014 | 859 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 88 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2015 | 386 | 0.090 |
Why?
|
| Quality of Life | 1 | 2014 | 459 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2015 | 1961 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 468 | 0.090 |
Why?
|
| DNA | 1 | 2013 | 549 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 87 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 87 | 0.090 |
Why?
|
| Inflammation | 2 | 2014 | 577 | 0.090 |
Why?
|
| Kidney Diseases | 2 | 2008 | 159 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 80 | 0.080 |
Why?
|
| DNA Replication | 1 | 2009 | 148 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 383 | 0.080 |
Why?
|
| Lipids | 1 | 2010 | 222 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 211 | 0.080 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2008 | 7 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 15 | 0.080 |
Why?
|
| Mice | 3 | 2021 | 5668 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2008 | 25 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2009 | 309 | 0.080 |
Why?
|
| HIV Infections | 1 | 2021 | 2207 | 0.080 |
Why?
|
| Brain | 1 | 2015 | 1268 | 0.080 |
Why?
|
| Arginine | 1 | 2008 | 62 | 0.080 |
Why?
|
| Nitric Oxide Synthase | 1 | 2008 | 103 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2007 | 27 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2008 | 115 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 2009 | 287 | 0.080 |
Why?
|
| Age Distribution | 1 | 2008 | 223 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 322 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2021 | 224 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 206 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2561 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2009 | 878 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2006 | 37 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2020 | 1318 | 0.070 |
Why?
|
| Animals | 4 | 2021 | 14307 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2009 | 751 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 406 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 336 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2020 | 74 | 0.070 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2004 | 1 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 222 | 0.060 |
Why?
|
| Symporters | 1 | 2004 | 11 | 0.060 |
Why?
|
| Genomics | 2 | 2004 | 201 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1300 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2005 | 135 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 465 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1149 | 0.060 |
Why?
|
| Models, Biological | 1 | 2007 | 642 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 580 | 0.060 |
Why?
|
| Iron Overload | 2 | 2014 | 7 | 0.060 |
Why?
|
| E-Selectin | 1 | 2023 | 19 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2003 | 69 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 2128 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2023 | 269 | 0.050 |
Why?
|
| Kringles | 1 | 2021 | 5 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2017 | 613 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2021 | 62 | 0.050 |
Why?
|
| Homozygote | 2 | 2011 | 75 | 0.050 |
Why?
|
| Phylogeny | 1 | 2004 | 612 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 176 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 137 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2011 | 188 | 0.050 |
Why?
|
| Hypertension | 1 | 2008 | 770 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 114 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2023 | 1802 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2014 | 149 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1681 | 0.040 |
Why?
|
| Neutrophils | 1 | 2020 | 124 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 707 | 0.040 |
Why?
|
| Acute Disease | 2 | 2011 | 141 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1152 | 0.040 |
Why?
|
| Age Factors | 2 | 2011 | 1007 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2017 | 86 | 0.040 |
Why?
|
| Uveitis | 1 | 2016 | 5 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 46 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2016 | 65 | 0.030 |
Why?
|
| Recurrence | 1 | 2016 | 125 | 0.030 |
Why?
|
| Rest | 1 | 2015 | 25 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 55 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2016 | 87 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 84 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 13 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2015 | 120 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2015 | 108 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 235 | 0.030 |
Why?
|
| Hemin | 1 | 2014 | 5 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 17 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 31 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 63 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 151 | 0.030 |
Why?
|
| alpha-Globins | 1 | 2014 | 3 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 101 | 0.030 |
Why?
|
| Walking | 1 | 2014 | 64 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 7 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 150 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2014 | 156 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 39 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 628 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2012 | 26 | 0.030 |
Why?
|
| Registries | 1 | 2014 | 330 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 40 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2014 | 298 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 195 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 18 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 286 | 0.030 |
Why?
|
| Hemoglobin, Sickle | 1 | 2011 | 13 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 37 | 0.030 |
Why?
|
| Exercise Test | 1 | 2011 | 68 | 0.030 |
Why?
|
| Exons | 1 | 2011 | 80 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2014 | 897 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 79 | 0.030 |
Why?
|
| Uric Acid | 1 | 2011 | 26 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2011 | 90 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2005 | 469 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 115 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 298 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 424 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 641 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 727 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 392 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 430 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 570 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 129 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 271 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 639 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 1289 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 431 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 194 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Citrulline | 1 | 2008 | 7 | 0.020 |
Why?
|
| Creatine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 229 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 901 | 0.020 |
Why?
|
| Mitogens | 1 | 2007 | 10 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 17 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 72 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 256 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2011 | 775 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 253 | 0.020 |
Why?
|
| Leukocytes | 1 | 2007 | 68 | 0.020 |
Why?
|
| Oxygen | 1 | 2008 | 193 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2007 | 74 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 217 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2005 | 48 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2008 | 871 | 0.020 |
Why?
|
| Gene Components | 1 | 2004 | 2 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 485 | 0.020 |
Why?
|
| Base Composition | 1 | 2004 | 22 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 58 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2004 | 59 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 550 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1490 | 0.020 |
Why?
|
| Species Specificity | 1 | 2004 | 233 | 0.020 |
Why?
|
| Candida | 1 | 2003 | 32 | 0.010 |
Why?
|